Analysis of Segments and Major Growth Areas in the Non-Viral Drug Delivery Systems Market

The non-viral drug delivery systems market is set to experience significant expansion over the coming years, driven by breakthroughs in technology and increasing demand for advanced therapeutics. This evolving sector is gaining attention as it offers promising alternatives to traditional viral vectors, enabling safer and more efficient delivery of genetic and molecular medicines. Here's a detailed examination of the market's size, key players, prevailing trends, and important segments shaping its future.

Anticipated Market Size of the Non-Viral Drug Delivery Systems Market by 2030
The non-viral drug delivery systems market is projected to grow swiftly, reaching a value of $19.07 billion by 2030. This impressive growth corresponds to a compound annual growth rate (CAGR) of 14.1%. Several factors are fueling this expansion, including progress in polymer-based carrier technologies, an upswing in RNA and DNA therapeutic developments, and heightened investment in personalized medicine approaches. Moreover, the rise of contract development and manufacturing organizations (CDMOs) and increased collaborations between pharmaceutical companies and academic institutions are further propelling market growth. Key trends to watch during this period include a growing preference for non-viral delivery platforms in targeted therapies, expanded use of nanoparticles and liposome carriers, a focus on minimizing immune responses while improving safety, and ongoing advancements in personalized and targeted treatment options alongside CDMO growth and academic partnerships.

Download a free sample of the non-viral drug delivery systems market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Market Leaders Driving Innovations in Non-Viral Drug Delivery Systems
Several leading companies are instrumental in advancing the non-viral drug delivery systems space. Notable players include Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, and Curapath Inc.

A significant development occurred in September 2023 when SOHM Inc., a US pharmaceutical firm, acquired ABBIE from CGA 369 for $10 million. This strategic acquisition enhances SOHM's capabilities in delivering large genetic payloads via integrase-based, non-viral tools. ABBIE is being developed as an off-the-shelf gene-editing kit, with plans to commercialize in 2024 and initiate human clinical trials by late 2025. CGA 369 is a US-based biotech company specializing in integrase-based non-viral gene-editing and genetic payload delivery technologies.

View the full non-viral drug delivery systems market report:
https://www.thebusinessresearchcompany.com/report/non-viral-drug-delivery-systems-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Drivers Propelling Advances in the Non-Viral Drug Delivery Market
Advancements in formulation technologies, especially polymer-based carriers, are critical factors driving growth in this market. These carriers enhance the stability and delivery efficiency of RNA and DNA therapeutics, which are becoming increasingly central to next-generation treatments. The expanding landscape of personalized medicine also plays a substantial role, as customized therapies require innovative delivery platforms that are both safe and effective.

In addition, growing investments and partnerships between pharmaceutical companies and academic institutions are accelerating research and development efforts. The expansion of contract development and manufacturing organizations (CDMOs) provides scalable solutions and expert support, allowing faster and more cost-effective production and testing of non-viral delivery systems.

Emerging Trends Highlighting Innovations in Non-Viral Drug Delivery Systems
One major trend in the industry is the adoption of pre-optimized ionizable lipid mix systems designed to facilitate the development and delivery of RNA-based drugs. These sophisticated formulations enable efficient encapsulation of RNA molecules into lipid nanoparticles, ensuring better payload protection, stability, and precise targeting for gene therapy applications.

For example, in September 2024, US-based biotechnology company Cytiva introduced an RNA delivery lipid nanoparticle (LNP) kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This kit includes a ready-to-use ionizable lipid mix that supports rapid screening and validation of RNA payloads, particularly useful for infectious disease vaccine research. The system integrates with automated microfluidic platforms, supports scalable manufacturing with GMP-grade materials, and provides users with standardized protocols and proof-of-concept data, guiding projects from early discovery stages to clinical trials.

Structural Breakdown of Key Segments in the Non-Viral Drug Delivery Systems Market
The report categorizes the non-viral drug delivery systems market based on several important segments:

1) Type of Molecule Delivered:
- Biologics
- Small Molecules

2) Type of Biologics Delivered:
- Ribonucleic Acid (RNA)
- Deoxyribonucleic Acid (DNA)
- Proteins or Peptides
- Antibodies

3) End User:
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Development and Manufacturing Organizations (CDMOs)
- Hospitals and Clinics

Further subcategories include:

- For Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
- For Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs

This segmentation provides a comprehensive view of the various components and applications within the non-viral drug delivery systems market, highlighting its diverse and rapidly evolving nature.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.